125 related articles for article (PubMed ID: 22759092)
41. Statistical analysis in cancer clinical trials.
Jeong JH
Anticancer Drugs; 2008 Feb; 19 Suppl 1():S9-10. PubMed ID: 18340243
[TBL] [Abstract][Full Text] [Related]
42. The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Herold CI; Blackwell KL
Breast; 2008 Jan; 17 Suppl 1():S15-24. PubMed ID: 18279763
[TBL] [Abstract][Full Text] [Related]
43. CNCF podcast: postoperative tamoxifen in women with ductal carcinoma in situ.
Lisy K
Int J Nurs Pract; 2014 Dec; 20(6):685. PubMed ID: 25532882
[No Abstract] [Full Text] [Related]
44. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Mouridsen HT; Robert NJ
MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
[TBL] [Abstract][Full Text] [Related]
45. [Radiotherapy and tamoxifen facilitate breast-preserving treatment of ductal carcinoma in situ of the breast].
Sautter-Bihl ML
Strahlenther Onkol; 1999 Dec; 175(12):620-1. PubMed ID: 10633790
[No Abstract] [Full Text] [Related]
46. Current controversies in the treatment of ductal carcinoma in situ of the breast.
Franceschini G; Terribile D; Magno S; Fabbri C; D'Alba P; Chiesa F; Di Leone A; Scafetta I; Masetti R
Ann Ital Chir; 2008; 79(3):151-5. PubMed ID: 18958961
[TBL] [Abstract][Full Text] [Related]
47. Tamoxifen in the treatment of advanced breast cancer. Clinical experience at Siriraj Hospital.
Tepmongkol P; Suphaphongs N; Chantarakul N; Thansakul A
J Med Assoc Thai; 1986 Feb; 69(2):96-102. PubMed ID: 3011939
[No Abstract] [Full Text] [Related]
48. New stars in the sky of treatment for early breast cancer.
Piccart-Gebhart MJ
N Engl J Med; 2004 Mar; 350(11):1140-2. PubMed ID: 15014188
[No Abstract] [Full Text] [Related]
49. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.
Hird RB; Chang A; Cimmino V; Diehl K; Sabel M; Kleer C; Helvie M; Schott A; Young J; Hayes D; Newman L
Cancer; 2006 May; 106(10):2113-8. PubMed ID: 16596655
[TBL] [Abstract][Full Text] [Related]
50. Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial.
Baum M
Cancer Control; 2004; 11(4):217-21. PubMed ID: 15284712
[TBL] [Abstract][Full Text] [Related]
51. Tamoxifen Acceptance and Adherence among Patients with Ductal Carcinoma In Situ (DCIS) Treated in a Multidisciplinary Setting.
Karavites LC; Kane AK; Zaveri S; Xu Y; Helenowski I; Hansen N; Bethke KP; Rasmussen-Torvik LJ; Khan SA
Cancer Prev Res (Phila); 2017 Jul; 10(7):389-397. PubMed ID: 28559459
[TBL] [Abstract][Full Text] [Related]
52. Tamoxifen hits the target in situ.
Wilcken NR
Lancet; 1999 Jun; 353(9169):1986-7. PubMed ID: 10376607
[No Abstract] [Full Text] [Related]
53. Chemoprevention in breast cancer.
Vogel V
Clin Adv Hematol Oncol; 2005 Jul; 3(7):531-3. PubMed ID: 16167032
[No Abstract] [Full Text] [Related]
54. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.
Fontein DB; Seynaeve C; Hadji P; Hille ET; van de Water W; Putter H; Kranenbarg EM; Hasenburg A; Paridaens RJ; Vannetzel JM; Markopoulos C; Hozumi Y; Bartlett JM; Jones SE; Rea DW; Nortier JW; van de Velde CJ
J Clin Oncol; 2013 Jun; 31(18):2257-64. PubMed ID: 23610112
[TBL] [Abstract][Full Text] [Related]
55. Tumor lysis syndrome after tamoxifen flare.
Cech P; Block JB; Cone LA; Stone R
N Engl J Med; 1986 Jul; 315(4):263-4. PubMed ID: 3014336
[No Abstract] [Full Text] [Related]
56. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma.
Nakhlis F; Lazarus L; Hou N; Acharya S; Khan SA; Staradub VL; Rademaker AW; Morrow M
J Am Coll Surg; 2005 Nov; 201(5):688-94. PubMed ID: 16256910
[TBL] [Abstract][Full Text] [Related]
57. Biology and treatment of ductal carcinoma in situ.
Irvine T; Fentiman IS
Expert Rev Anticancer Ther; 2007 Feb; 7(2):135-45. PubMed ID: 17288525
[TBL] [Abstract][Full Text] [Related]
58. Estrogen and progesterone receptors in breast cancer.
Ma CX
Clin Adv Hematol Oncol; 2011 May; 9(5):385-6. PubMed ID: 21685867
[No Abstract] [Full Text] [Related]
59. Acceptance and adherence of oral endocrine therapy in women with metastatic breast cancer: exacampania group study.
Addeo R; Iodice P; Maiorino L; Febbraro A; Incoronato P; Pisano A; Bianco M; Mabilia R; Riccardi F; Del Prete S
Breast J; 2015; 21(3):326-8. PubMed ID: 25790292
[No Abstract] [Full Text] [Related]
60. Can some DCIS patients avoid adjuvant therapy? Still unknown.
Schmidt C
J Natl Cancer Inst; 2011 Apr; 103(7):530-1. PubMed ID: 21436062
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
